Introduction
The prognosis of differentiated thyroid carcinoma (DTC) is known to be excellent after surgical treatment and radioactive iodine (RAI) followed by thyrotropin suppressive therapy. 1) However, approximately half of locally advanced or metastatic DTCs are refractory to RAI therapy and have a very poor prognosis. 2, 3) Sorafenib, an oral multi-kinase inhibitor that affects both tumor cell proliferation and angiogenesis, has emerged as an effective therapeutic option for patients with advanced RAI-refractory DTC. 4) It has a relatively well-tolerated toxicity profile compared with conventional cytotoxic chemotherapy. However, rare but fatal adverse events, such as hemorrhage, myocardial infarction, sepsis, and sudden death, have been reported. 4, 5) Tracheoesophageal fistula (TEF), which is one of them, is a life threatening complication in malignancy such as lung, esophagus, or head and neck cancer. [6] [7] [8] [9] [10] TEF formation because of DTC is extremely rare and there have been no previous reports of this phenomenon as a complication of using sorafenib. Herein, we report a patient with TEF associated with rapid tumor regression of locally advanced papillary thyroid carcinoma (PTC) after treatment with sorafenib.
Case Report
A 71-year-old woman presented with a 1-week history of hemoptysis and progressive dyspnea Follow up CT image was performed every 1 month after feeding through the jejunostomy tube to evaluate the change in TEF and its size. After 3 months, esophagography showed no extraluminal leakage of contrast media ( Fig. 2D) and TEF was found to be in a healing state on tracheobronchial CT (Fig. 2E, F) . She started oral feeding and jejunostomy tube was removed.
Our patient remains alive without signs of recurrent TEF, and the tumor remains stable at 15 months after the discontinuation of sorafenib. She underwent radiofrequency ablation for a right level II cervical lymph node metastasis after withdrawal of sorafenib and this lesion has also been stable up to the most recent follow-up.
Discussion
Patients with RAI refractory DTC have a poor prognosis and a long-term overall survival of only 10%.
11)
No definite therapeutic option was available until sor- The prognosis of a patient who develops TEF as a complication of a malignancy is very poor. In the previously reported cases by Blevins et al. 13) , all of the patients died within 2 months of the formation of aerodigestive fistulas that resulted from hemorrhage, infection, or respiratory distress. Our present case suggests that early diagnosis of TEF and immediate therapeutic interventions for enteric feeding to prevent life threatening complications, such as aspiration pneumonia, are critical to improve the survival outcomes and quality of life.
In conclusion, TEF formation can be a progressively deteriorating complication in patients administered antiangiogenic agents with tumors directly invading vital organs including esophagus and trachea, previous radiation therapy, and instrumentation of the trachea or esophagus. As sorafenib grows in importance in the treatment of RAI refractory DTC and more antiangiogenic TKIs are being developed, greater awareness when using these drugs in high risk patients should be made for this potential complication.
